INTENSITY THERAPEUTICS, INC. 8-K

What Happened

• On May 7, 2026, Intensity Therapeutics, Inc. (INTS) announced and released its financial results for the three months ended March 31, 2026. The company attached a press release as Exhibit 99.1 to the Form 8-K. The report was signed by CEO Lewis H. Bender.
• The filing notes that the information in the report is not automatically “filed” for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings unless expressly stated. It also includes the standard forward-looking statements caution referencing the company’s 2026 Form 10-K (filed March 27, 2026) and its Form 10-Q (filed May 7, 2026).

Key Details

• Filing date: May 7, 2026; reporting period: quarter ended March 31, 2026.
• Exhibit included: Press Release (Exhibit 99.1).
• Inline XBRL cover page included (Exhibit 104).
• Report signed by CEO Lewis H. Bender.

Why It Matters

• This 8-K notifies investors that the company has published its quarterly financial results and related press release; those materials will contain the specific earnings, revenue, cash and operational details investors use to assess performance.
• Investors should read the attached press release and the company’s May 7, 2026 Form 10-Q and March 27, 2026 Form 10-K for the full financial figures, context, and the risk disclosures referenced in the forward-looking statements.